News

June 15, 2017June 15, 2017

Patients Should Have More Input in eHealth Technologies’ Design, Study Finds

News

Patients with inflammatory bowel disease (IBD) are open to engaging with electronic health (eHealth) technologies as potential solutions for better disease self-management. This suggests that eHealth could be a way ... Read more

June 14, 2017

More Bowel Disease Patients Are Switching Therapies Than a Year Ago, Report Says

News

More inflammatory bowel disease patients are switching biologic therapies than in 2016, according to a report by Spherix Global Insights RealWorld Dynamix. The appearance of Janssen’s Stelara (ustekinumab) — approved ... Read more

June 13, 2017June 13, 2017

Corrona Enrolls First Patient in Novel IBD Registry to Study Crohn’s Disease, Ulcerative Colitis

IBD News, News

Corrona, a provider of U.S. disease registries, has enrolled the first patient in its novel inflammatory bowel disease (IBD) registry, launched in May 2017. This is the first national registry ... Read more

June 12, 2017

Depression May Influence Progression of Crohn’s Disease, Study Finds

Crohn's Disease, News

Depression is a psychological condition that is twice as prevalent in patients with inflammatory bowel disease (IBD) than in healthy people. Despite its high incidence, there is no clear evidence supporting ... Read more

June 9, 2017June 9, 2017

Stem Cell Therapy Potentially Effective in Crohn’s Disease, but Concerns Remain, Review Finds

Crohn's Disease, News

Stem cell therapy was found to be potentially effective and a possible alternative treatment for patients with refractory active Crohn’s disease, according to a meta–analysis review study. Toxicity remains the most ... Read more

June 8, 2017June 8, 2017

FDA Approves Mesalamine Delayed–Release Tablets, Generic of Lialda, for UC

News

The U.S. Food and Drug Administration (FDA) has given final approval for Zydus Cadila to market Mesalamine Delayed–Release Tablets USP, a generic version of Lialda, in the U.S. to treat ulcerative colitis (UC). The announcement follows news ... Read more

June 7, 2017June 7, 2017

Seres Completes Enrollment for SER-287 Phase 1b Clinical Trial in Patients with UC

News

All patients with mild-to-moderate ulcerative colitis (UC) have been enrolled in Seres Therapeutics‘ ongoing Phase 1b clinical study evaluating the company’s drug therapy candidate, SER-287. The ongoing randomized, placebo-controlled, multiple-dose, ... Read more

June 6, 2017June 6, 2017

Human, Mouse Studies Suggest MicroRNA Has Potential to Treat Crohn’s Disease, Ulcerative Colitis

News

Synthetic versions of a specific microRNA produced by white blood cells can reduce intestinal inflammation in mice, suggesting a new therapeutic approach to treating Crohn’s disease and ulcerative colitis, according ... Read more

June 5, 2017

Canadian Bowel Disease Experts and Patients Develop Five Key Treatment Recommendations

News

Crohn’s and Colitis Canada and the Canadian Association of Gastroenterology have developed a list of five key recommendations that they urge patients with Crohn’s and ulcerative colitis to discuss with their physicians. The ... Read more

June 2, 2017June 2, 2017

Inflammatory Disease Database to Aid Maker of Ulcerative Colitis and Crohn’s Therapies

News

A collaboration with Spanish company IMIDomics will allow biopharmaceutical company Celgene to identify new targets and biomarkers, support further drug development, and classify patients for clinical trials in inflammatory bowel ... Read more